# Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

> **NCT05247203** · PHASE1 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 92 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Telitacicept
- **DRUG:** standard therapy

## Key facts

- **NCT ID:** NCT05247203
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-11-13
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247203, "Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05247203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*